Sharmistha Acharya

Title: Sharmistha Acharya: Innovator in Antibody Engineering

Introduction

Sharmistha Acharya is a prominent inventor based in Summit, NJ (US). She has made significant contributions to the field of biotechnology, particularly in the engineering of antibodies for targeted cancer therapy. Her innovative work focuses on enhancing the effectiveness of treatments for tumor cells while minimizing effects on normal cells.

Latest Patents

Sharmistha Acharya holds a patent for her groundbreaking invention titled "Engineering of an antibody for tumor-selective binding of CD47." This patent describes antibodies that include at least one Fab portion binding to CD47 and another Fab portion binding to the tumor-associated antigen (TAA) CD20. The unique design allows the Fab portion that binds CD47 to exhibit low affinity for CD47, while the Fab portion that binds CD20 shows high affinity for CD20. This selective binding mechanism enables the antibody to block CD47 interaction with SIRPα in tumor cells, effectively targeting cancer while sparing normal cells.

Career Highlights

Sharmistha Acharya is currently employed at Celgene Corporation, where she continues to advance her research in antibody engineering. Her work has the potential to revolutionize cancer treatment by providing more effective therapeutic options for patients.

Collaborations

Sharmistha collaborates with talented colleagues, including Haralambos Hadjivassiliou and Dan Zhu, who contribute to her research efforts and help drive innovation within the company.

Conclusion

Sharmistha Acharya's contributions to antibody engineering exemplify the impact of innovative thinking in biotechnology. Her work not only advances scientific knowledge but also holds promise for improving cancer treatment outcomes.